Real world study in Italian public hospital with Efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors
BackgroundMyasthenia gravis (MG) is an autoimmune neuromuscular disorder caused by IgG autoantibodies targeting the neuromuscular junction. Recycling of IgG is mediated by the neonatal Fc receptor (FcRn). Efgartigimod, an Fc fragment of human IgG1, has demonstrated efficacy in MG; however, the clini...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2025-05-01
|
| Serie: | Frontiers in Neurology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1555068/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|